#1 Clinical Trials Search in Europe

JX10

The ORION study is a significant clinical trial examining JX10, a promising thrombolytic agent for patients with acute ischemic stroke who seek medical care between 4.5 and 24 hours after symptom onset. This multicenter, randomized study aims to determine whether JX10 can improve functional outcomes compared to placebo and assess its safety profile, particularly regarding the risk of brain bleeding. The trial is being conducted in two parts, testing different doses (1mg/kg and 3mg/kg) to identify the optimal treatment approach for patients with late-presenting strokes, potentially expanding treatment options beyond the current narrow time window for stroke intervention.

Table of Contents

What is JX10?

JX10 is a thrombolytic agent, which is a type of medication designed to dissolve blood clots. Thrombolytic agents work by breaking down the proteins that form blood clots, helping to restore blood flow to areas affected by blockages[1]. In the context of stroke treatment, these medications can be crucial for restoring blood flow to the brain when a clot has blocked an artery.

What Conditions Does JX10 Treat?

JX10 is being investigated specifically for treating Acute Ischemic Stroke (AIS)[1]. An ischemic stroke occurs when a blood clot blocks an artery supplying blood to the brain. This blockage prevents brain tissue from receiving oxygen and nutrients, causing brain cells to die within minutes. The damage can lead to various disabilities, including paralysis, speech difficulties, and even death, depending on which area of the brain is affected and how quickly treatment is received.

What makes JX10 particularly noteworthy is that it’s being studied for use in patients who arrive at the hospital between 4.5 and 24 hours after their stroke symptoms begin[1]. This is important because current standard thrombolytic treatments typically must be administered within 4.5 hours of symptom onset. JX10 could potentially extend this treatment window, allowing more patients to receive clot-dissolving therapy.

How JX10 is Being Studied

JX10 is currently being evaluated in a clinical trial called “Optimizing Reperfusion to Improve Outcomes and Neurologic Function” (ORION)[1]. This is a large, well-designed study that has several important features:

  • Multicenter: The study is taking place at multiple hospitals and medical centers, which helps ensure that results can be applied to diverse patient populations.
  • Double-blind: Neither the patients nor the doctors directly treating them know whether they’re receiving JX10 or placebo. This helps prevent bias in assessing results.
  • Placebo-controlled: Some participants receive an inactive substance (placebo) instead of JX10, which allows researchers to determine if JX10’s effects are truly due to the medication itself.
  • Randomized: Patients are assigned to either JX10 or placebo groups by chance, which helps ensure the groups are similar in all other respects.
  • Phase 2/3: This indicates the study is at an advanced stage of clinical testing, evaluating both safety and effectiveness[1].

The study is divided into two parts. In Part 1, researchers are comparing different doses of JX10 to determine which works best. In Part 2, they will use the optimal dose identified in Part 1 to further evaluate the medication’s effectiveness[1].

Dosage Information

The ORION study is testing two different doses of JX10[1]:

  • 1 mg/kg body weight
  • 3 mg/kg body weight

These doses are being evaluated in Part 1 of the study to determine which provides the best balance of effectiveness and safety. The most effective dose will then be used in Part 2 of the study[1].

Effectiveness Measures

The ORION study is measuring the effectiveness of JX10 in several ways[1]:

  • Modified Rankin Scale (mRS): This is a scale that measures the degree of disability or dependence in daily activities for people who have suffered a stroke. The scale ranges from 0 (no symptoms) to 6 (death). The main effectiveness measure is the proportion of patients who have a score of 0-1 at 90 days after treatment, indicating no or minimal symptoms.
  • Functional independence: Researchers are also looking at how many patients achieve “functional independence” (mRS score 0-2) at 90 days, meaning they can handle their own affairs without assistance, even if they have some symptoms.
  • Ordinal mRS analysis: This looks at the entire range of scores (0-6) to determine if JX10 helps patients achieve better outcomes across all levels of recovery[1].

Safety Concerns

As with all thrombolytic medications, there are important safety considerations with JX10. The main safety concern being evaluated is the risk of symptomatic intracranial hemorrhage (bleeding in the brain)[1]. This is a known potential complication of thrombolytic therapy that can be serious or life-threatening.

The study is specifically measuring:

  • The incidence of symptomatic intracranial hemorrhage within 36 hours after receiving the medication
  • The occurrence of major bleeding within 24 hours and 14 days of treatment
  • All adverse events (side effects) and serious adverse events that occur during the study period[1]

Potential Benefits

If JX10 proves to be safe and effective, it could provide several important benefits for stroke patients[1]:

  • Extended treatment window: Currently, the standard thrombolytic treatment (tPA or alteplase) must generally be given within 4.5 hours after stroke symptoms begin. JX10 is being studied for use up to 24 hours after stroke onset, which could dramatically increase the number of patients eligible for this type of treatment.
  • Improved outcomes: The hope is that JX10 will help more patients recover with minimal or no disability following a stroke.
  • Potentially safer profile: While safety is still being evaluated, researchers are hoping that JX10 might offer effective clot dissolution with a manageable safety profile, even when given in the extended time window[1].
Study Aspect Details
Study Name ORION (Optimizing Reperfusion to Improve Outcomes and Neurologic Function)
Study Type Multicenter, double-blind, placebo-controlled, randomized, parallel-group, Phase 2/3 study
Drug Being Tested JX10 (a thrombolytic agent)
Condition Acute Ischemic Stroke (AIS)
Treatment Window Patients presenting 4.5 to 24 hours after stroke onset
Study Structure Part 1: Testing JX10 at 1mg/kg and 3mg/kg vs. placebo
Part 2: Testing optimal JX10 dose from Part 1 vs. placebo
Primary Outcome Measures – Efficacy: Proportion of participants with no or minimal symptoms (mRS score 0-1) at 90 days
– Safety: Incidence of symptomatic intracranial hemorrhage within 36 hours
Secondary Outcome Measures – Ordinal mRS score distribution at 90 days
– Proportion of participants with functional independence (mRS 0-2) at 90 days
– Incidence of adverse events and serious adverse events
– Incidence of major bleeding within 24 hours and 14 days of treatment

FAQ

  • What is JX10 and how does it work? JX10 is a thrombolytic agent being studied for acute ischemic stroke treatment. Thrombolytic medications work by dissolving blood clots that block blood vessels in the brain during an ischemic stroke. By restoring blood flow (reperfusion), JX10 aims to limit brain damage and improve recovery outcomes for stroke patients.
  • Why is the ORION study significant for stroke treatment? The ORION study is significant because it examines treatment for stroke patients who arrive at the hospital between 4.5 to 24 hours after symptom onset. Current standard thrombolytic treatments are typically limited to within 4.5 hours of stroke onset. If successful, JX10 could potentially extend the treatment window, allowing many more stroke patients to receive effective treatment.
  • How is the ORION clinical trial structured? The ORION trial is a multicenter, double-blind, placebo-controlled, randomized study conducted in two parts. In Part 1, participants are randomly assigned to receive either JX10 at 1mg/kg, JX10 at 3mg/kg, or a placebo. In Part 2, participants receive either the optimal JX10 dose (determined from Part 1 results) or a placebo. This design helps researchers determine both the effectiveness and the optimal dosage of the medication.
  • What outcomes are researchers measuring in the JX10 clinical trial? The primary outcomes researchers are measuring include: 1) Efficacy – the proportion of patients with no or minimal stroke symptoms (measured by a modified Rankin Scale score of 0-1) at 90 days after treatment, and 2) Safety – the incidence of symptomatic intracranial hemorrhage (brain bleeding) within 36 hours after randomization. Secondary outcomes include functional independence, the overall distribution of disability scores, and the incidence of adverse events and major bleeding.
  • What safety concerns are being monitored in the JX10 trial? The main safety concern being closely monitored is the risk of symptomatic intracranial hemorrhage (brain bleeding), which is a known potential complication of thrombolytic treatments. Researchers are specifically tracking this within 36 hours of treatment. Additionally, they're monitoring all adverse events, serious adverse events, and major bleeding incidents within 24 hours and up to 14 days after treatment to establish a comprehensive safety profile of JX10.

Ongoing Clinical Trials on JX10

  • Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Finland France Germany Greece +7

Glossary

  • Acute Ischemic Stroke (AIS): A type of stroke that occurs when a blood clot blocks an artery supplying blood to the brain, causing brain tissue to be deprived of oxygen and nutrients. This leads to the death of brain cells and potential loss of brain function.
  • Thrombolytic Agent: A medication that dissolves blood clots. JX10 is being studied as a thrombolytic agent for treating strokes by breaking up the clots that block blood flow to the brain.
  • Reperfusion: The restoration of blood flow to an organ or tissue after it has been blocked. In stroke treatment, reperfusion refers to restoring blood flow to brain tissue affected by a clot.
  • Modified Rankin Scale (mRS): A commonly used scale to measure the degree of disability in stroke patients. The scale ranges from 0 (no symptoms) to 6 (death), with scores of 0-1 indicating no or minimal symptoms, and 0-2 indicating functional independence.
  • Symptomatic Intracranial Hemorrhage: Bleeding inside the skull that causes noticeable symptoms. This is a potential serious complication of thrombolytic therapy for stroke.
  • Double-Blind Study: A research design where neither the participants nor the researchers know who is receiving the actual treatment versus the placebo until after the study is completed. This helps prevent bias in the results.
  • Placebo: An inactive substance that looks like the drug being tested but has no therapeutic effect. It's used as a control in clinical trials to help determine the true effect of the experimental treatment.
  • Randomized Controlled Trial: A type of scientific experiment where participants are randomly assigned to either a treatment or control group. This is considered the gold standard for testing the effectiveness of medical treatments.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment, regardless of whether it is considered related to the treatment.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization or extension of existing hospitalization, results in persistent or significant disability, or is a congenital anomaly/birth defect.
  • Functional Independence: In stroke research, this typically refers to a patient's ability to perform daily activities with minimal or no assistance, usually measured as a modified Rankin Scale score of 0-2.
  • Phase 2/3 Study: A clinical trial that combines elements of both Phase 2 (which evaluates effectiveness and looks for side effects) and Phase 3 (which confirms effectiveness, monitors side effects, and compares to commonly used treatments) in a single study design.

References

  1. https://clinicaltrials.gov/study/NCT06990867